跳至主要内容
临床试验/NL-OMON47892
NL-OMON47892招募中不适用

Feasibility of MRI guided focal high-dose-rate brachytherapy for localized prostate cancer - Feasibility of MRI guided focal HDR-BT for localized prostate cancer

niversitair Medisch Centrum Utrecht0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age >= 65 years
  • - Patients with prostate cancer, T stage < T3, Gleason <=7, Prostate Specific
  • Antigen (PSA) <10 ng/ml
  • - Tumour location technically feasible for brachytherapy
  • - Karnofski score >=70
  • - Written informed consent
  • - Fit for spinal anaesthesia

排除标准

  • - Previous pelvic radiotherapy for another malignancy
  • - Previous surgery or transurethral resection of the prostate
  • - Prostate cancer recurrence
  • - Patients who meet exclusion criteria for MRI following the protocol of the
  • radiology department of the UMC Utrecht
  • - International Prostate Symptom Score (IPSS) >15
  • - Anticoagulant administration continuously required, except for platelet
  • aggregation inhibitors (for example Ascal/Persantin)
  • - Discongruence between prostate biopsies and MR imaging

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验